To recover your password please fill in your email address
Please fill in below form to create an account with us
A phase III randomized study of BBI608 and best supportive care versus placebo and best supportive care in patients with pretreated advanced colorectal carcinoma.
|
Trial Summary: |
The primary objective of CO.23 is to compare Overall Survival (OS), defined as the time from randomization until death from any cause, in patients with pre-treated advanced colorectal carcinoma treated with BBI608 plus best supportive care versus placebo plus best supportive care. |
|
Supported By: |
Boston Biomedical Inc |
|
Eligibility: |
Adults 18 and over. Histologically confirmed advanced colorectal cancer that is unresectable. |
|
Registration ID: |
ACTRN12613000556741 |
|
Participation: |
International |
|
Australian Lead Group: |
|
|
Status: |
closed |
|
Activation Date: |
27/08/2013 |
|
Chairs: |
Dr Louise Nott |
|
Contact: |